RNA, U6 small nuclear 986, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-986P profile across patient tissues and cancer cell-line models. RNU6-986P expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, RNU6-986P is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, RNU6-986P RNA expression shows 7,355 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight THCA, PRAD, and LAML as cancer lineages where RNU6-986P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-986P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-986P survival associations across molecular data types. RNU6-986P RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-986P RNA expression–survival associations across cancer types. High RNU6-986P expression shows unfavorable associations in THCA, ACC, BLCA and SKCM, but favorable associations in LUAD and LAML. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for RNU6-986P RNA expression.
This table summarizes RNU6-986P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-986P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-986P shows higher tumor expression in PRAD. The PRAD box plot shows higher RNU6-986P RNA expression in tumor versus normal tissue (log2 FC = +0.161, t-test p = .001).
This table shows molecular features associated with RNU6-986P in patient tissues and cancer cell lines. In patient samples, RNU6-986P shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
